NDLI: α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis

Content Provider	PubMed Central
Author	Wu, C. Y. Feng, Y. Qian, G. C. Wu, J. H. Luo, J. Wang, Y. Chen, G. J. Wang, Z. J. Guo, X. K.
Abstract	Myocarditis is an inflammation of the myocardium which often follows virus infections. Coxsackievirus B3 (CVB3), as a marker of the enterovirus group, is one of the most important infectious agents of virus-induced myocarditis. Using a CVB3-induced myocarditis model, we show that injection α-galactosylceramide (α-GalCer), a ligand for invariant natural killer (NK) T (iNK T) cells, can protect the mice from viral myocarditis. After the systemic administration of α-GalCer in CVB3 infected mice, viral transcription and titres in mouse heart, sera and spleen were reduced, and the damage to the heart was ameliorated. This is accompanied by a better disease course with an improved weight loss profile. Compared with untreated mice, α-GalCer-treated mice showed high levels of interferon (IFN)-γ and interleukin (IL)-4, and reduced proinflammatory cytokines and chemokines in their cardiac tissue. Anti-viral immune response was up-regulated by α-GalCer. Three days after CVB3 infection, α-GalCer-administered mice had larger spleens. Besides NK T cells, more macrophages and CD8+ T cells were found in these spleens. Upon stimulation with phorbol myristate acetate plus ionomycin, splenocytes from α-GalCer-treated mice produced significantly more cytokines [including IFN-γ, tumour necrosis factor-α, IL-4 and IL-10] than those from untreated mice. These data suggest that administration of α-GalCer during acute CVB3 infection is able to protect the mice from lethal myocarditis by local changes in inflammatory cytokine patterns and enhancement of anti-viral immune response at the early stage. α-GalCer is a potential candidate for viral myocarditis treatment. Our work supports the use of anti-viral treatment early to reduce the incidence of virus-mediated heart damage.
Related Links	http://dx.doi.org/10.1111/j.1365-2249.2010.04233.x
Starting Page	178
File Format	PDF
ISSN	13652249
e-ISSN	13652249
Journal	Clinical and Experimental Immunology
Issue Number	1
Volume Number	162
Language	English
Publisher	Blackwell Science Inc
Publisher Date	2010-10-01
Access Restriction	Open
Rights Holder	Blackwell Science Inc
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.

A Genetically Engineered Attenuated Coxsackievirus B3 Strain Protects Mice against Lethal Infection

VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment

Temperature-Sensitive Mutant of Coxsackievirus B3 Establishes Resistance in Neonatal Mice That Protects Them During Adolescence Against Coxsackievirus B3-Induced Myocarditis

A viral-specific CD4+ T cell response protects female mice from Coxsackievirus B3 infection

Coxsackievirus B3 infection induces anti-flavoprotein antibodies in mice

Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d

Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice

Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis

α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis

Similar Documents

-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.

A Genetically Engineered Attenuated Coxsackievirus B3 Strain Protects Mice against Lethal Infection

VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment

Temperature-Sensitive Mutant of Coxsackievirus B3 Establishes Resistance in Neonatal Mice That Protects Them During Adolescence Against Coxsackievirus B3-Induced Myocarditis

A viral-specific CD4+ T cell response protects female mice from Coxsackievirus B3 infection

Coxsackievirus B3 infection induces anti-flavoprotein antibodies in mice

Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d

Coxsackievirus B3-induced myocarditis: differences in the immune response of C57BL/6 and Balb/c mice

Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis

α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis